<DOC>
	<DOCNO>NCT01218477</DOCNO>
	<brief_summary>The purpose study determine safety tolerability combination BMS-833923 plus dasatinib patient chronic myeloid leukemia .</brief_summary>
	<brief_title>Dasatinib Combination Therapy With Smoothened ( SMO ) Inhibitor BMS-833923 Chronic Myeloid Leukemia ( CML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Key Inclusion Criteria Age ≥18 year Diagnosis chronic myeloid leukemia ( CML ) cytogenetic positive Philadelphia chromosome ( Ph+ ) , document Ph+ cell bone marrow assessment ( BMA ) ≤6 week prior treatment Either chronicphase CML , &lt; 15 % blast peripheral blood bone marrow , advancedphase CML , include Ph+ acute lymphoblastic leukemia ( ALL ) ( &gt; 5 % blast ) hematologic progression ≥15 % blast complete cytogenetic remission Resistance suboptimal response imatinib , dasatinib , nilotinib know T315I/A Ablkinase mutation . Key Exclusion Criteria Known Ablkinase T315I T315A mutation CCyR baseline Any serious uncontrolled medical disorder active infection would impair ability subject receive protocol therapy Uncontrolled significant cardiovascular disease Grade 3 high peripheral blood count Serum calcium phosphate lower limit normal Baseline hypomagnesemia amylase lipase least Grade 1 high Reduced renal function , define serum creatinine level &gt; 3*upper limit normal Prior therapy CML Ph+ ALL permit , follow restriction : Therapy permit corticosteroid , hydroxyurea , anagrelide prior start treatment first 4 week study 6 month long stem cell transplantation 28 day longer investigational agent 7 day longer standard chemotherapy agent Concomitant use medication know risk cause Torsades de Pointes Concomitant use strong inhibitor CYP3A4 isoenzyme</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>( Chronic Myeloid Leukemia-Chronic Phase Advanced )</keyword>
</DOC>